The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The efficacy of FLT3 and IDH1/2 inhibitors in patients with AML previously treated with venetoclax
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses advances made in the treatment of acute myeloid leukemia (AML), highlighting the value of FLT3 and IDH1/2 inhibitors. Dr Bewersdorf then shares insights into a retrospective analysis which investigated the efficacy of these targeted agents in patients with AML previously treated with venetoclax, and highlights the need for more research in this space. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
